212 related articles for article (PubMed ID: 21889550)
21. Propensity of Selaginella delicatula aqueous extract to offset rotenone-induced oxidative dysfunctions and neurotoxicity in Drosophila melanogaster: Implications for Parkinson's disease.
Girish C; Muralidhara
Neurotoxicology; 2012 Jun; 33(3):444-56. PubMed ID: 22521218
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
23. Attenuation of myocardial apoptosis by alpha-lipoic acid through suppression of mitochondrial oxidative stress to reduce diabetic cardiomyopathy.
Li CJ; Zhang QM; Li MZ; Zhang JY; Yu P; Yu DM
Chin Med J (Engl); 2009 Nov; 122(21):2580-6. PubMed ID: 19951573
[TBL] [Abstract][Full Text] [Related]
24. Astrocytes protect MN9D neuronal cells against rotenone-induced oxidative stress by a glutathione-dependent mechanism.
Cao Q; Wei LR; Lu LL; Zhao CL; Zhao HY; Yang H
Sheng Li Xue Bao; 2007 Jun; 59(3):253-9. PubMed ID: 17579777
[TBL] [Abstract][Full Text] [Related]
25. Neuroprotective effects of bee venom acupuncture therapy against rotenone-induced oxidative stress and apoptosis.
Khalil WK; Assaf N; ElShebiney SA; Salem NA
Neurochem Int; 2015 Jan; 80():79-86. PubMed ID: 25481089
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
27. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
28. Anti-apoptotic and neuroprotective effects of α-lipoic acid on spinal cord ischemia-reperfusion injury in rabbits.
Emmez H; Yildirim Z; Kale A; Tönge M; Durdağ E; Börcek AO; Uçankuş LN; Doğulu F; Kiliç N; Baykaner MK
Acta Neurochir (Wien); 2010 Sep; 152(9):1591-600; discussion 1600-1. PubMed ID: 20535507
[TBL] [Abstract][Full Text] [Related]
29. D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease.
Imamura K; Takeshima T; Kashiwaya Y; Nakaso K; Nakashima K
J Neurosci Res; 2006 Nov; 84(6):1376-84. PubMed ID: 16917840
[TBL] [Abstract][Full Text] [Related]
30. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Schmidt WJ; Alam M
J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
[TBL] [Abstract][Full Text] [Related]
31. N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.
Minelli A; Conte C; Prudenzi E; Cacciatore I; Cornacchia C; Taha E; Pinnen F
Free Radic Biol Med; 2010 Jul; 49(1):31-9. PubMed ID: 20307650
[TBL] [Abstract][Full Text] [Related]
32. Protocatechuic acid inhibits apoptosis by mitochondrial dysfunction in rotenone-induced PC12 cells.
Liu YM; Jiang B; Bao YM; An LJ
Toxicol In Vitro; 2008 Mar; 22(2):430-7. PubMed ID: 18082360
[TBL] [Abstract][Full Text] [Related]
33. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.
Xiong N; Long X; Xiong J; Jia M; Chen C; Huang J; Ghoorah D; Kong X; Lin Z; Wang T
Crit Rev Toxicol; 2012 Aug; 42(7):613-32. PubMed ID: 22574684
[TBL] [Abstract][Full Text] [Related]
35. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
[TBL] [Abstract][Full Text] [Related]
36. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy).
Stefanova N; Lundblad M; Tison F; Poewe W; Cenci MA; Wenning GK
Neurobiol Dis; 2004 Apr; 15(3):630-9. PubMed ID: 15056471
[TBL] [Abstract][Full Text] [Related]
37. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
[TBL] [Abstract][Full Text] [Related]
38. Docosahexaenoic acid protection in a rotenone induced Parkinson's model: Prevention of tubulin and synaptophysin loss, but no association with mitochondrial function.
Serrano-García N; Fernández-Valverde F; Luis-Garcia ER; Granados-Rojas L; Juárez-Zepeda TE; Orozco-Suárez SA; Pedraza-Chaverri J; Orozco-Ibarra M; Jiménez-Anguiano A
Neurochem Int; 2018 Dec; 121():26-37. PubMed ID: 30342962
[TBL] [Abstract][Full Text] [Related]
39. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
Dabbeni-Sala F; Di Santo S ; Franceschini D; Skaper SD; Giusti P
FASEB J; 2001 Jan; 15(1):164-170. PubMed ID: 11149904
[TBL] [Abstract][Full Text] [Related]
40. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine.
Pedrosa R; Soares-da-Silva P
Br J Pharmacol; 2002 Dec; 137(8):1305-13. PubMed ID: 12466240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
